Expert opinion on drug metabolism & toxicology · 2009
Modeling HCV kinetics under therapy using PK and PD information.
СтатьяПоддержка NIH: внешняя программаПоддержка правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shudo Emi, Ribeiro Ruy M, Perelson Alan S
Аннотация
BACKGROUND: Mathematical models have proven helpful in analyzing the virological response to antiviral therapy in hepatitis C virus (HCV) infected subjects.
OBJECTIVE: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.
METHODS: We formulate mathematical models and fit them by nonlinear least square regression to patient data to estimate model parameters. We compare the goodness of fit and parameter values estimated by different models statistically.
RESULTS/CONCLUSION: The best model for parameter estimation depends on the availability and the quality of data as well as the therapy used. We also discuss the mathematical models that will be needed to analyze HCV kinetic data from clinical trials with new antiviral drugs.
OBJECTIVE: To summarize the uses and limitations of different models for analyzing HCV kinetic data under pegylated IFN therapy.
METHODS: We formulate mathematical models and fit them by nonlinear least square regression to patient data to estimate model parameters. We compare the goodness of fit and parameter values estimated by different models statistically.
RESULTS/CONCLUSION: The best model for parameter estimation depends on the availability and the quality of data as well as the therapy used. We also discuss the mathematical models that will be needed to analyze HCV kinetic data from clinical trials with new antiviral drugs.